Sugi Predict

Sugi Predict / Compounds / SCHEMBL6663240

SCHEMBL6663240

SCHEMBL6663240

N#CCNCc1ccc(F)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.59
▸ CHRM2 P08172 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ PLA2G1B P04054 1/20 0.44
▸ ATG4B Q9Y4P1 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ DPP7 Q9UHL4 5/20 0.43
▸ MAPK1 P28482 1/20 0.42
▸ DPP4 P27487 1/20 0.42
▸ SCN8A Q9UQD0 1/20 0.41
▸ PYCR1 P32322 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13185941 0.81 CHRM2 (0.53) LMNACHRM2L3MBTL1CYP3A4CYP2D6
SCHEMBL5358152 0.80 CA12 (0.58) LMNAL3MBTL1CYP3A4CYP2D6CYP2C9
SCHEMBL184001 0.79 LMNA (0.77) LMNACHRM2L3MBTL1CYP3A4CYP2D6
SCHEMBL1796909 0.79 LMNA (0.77) LMNACHRM2L3MBTL1CYP3A4CYP2D6
SCHEMBL9045672 0.79 PYCR1 (0.66) LMNACHRM2L3MBTL1CYP3A4CYP2D6
SCHEMBL11445734 0.79 ANPEP (0.42) LMNACYP3A4ALDH1A1HTTPYCR1
SCHEMBL26672005 0.79 PYCR1 (0.66) LMNAL3MBTL1CYP2D6CYP2C19KMT2A
SCHEMBL11305587 0.79 CHRM2 (0.52) LMNACHRM2CYP2C9CYP2C19ALDH1A1
SCHEMBL653443 0.78 MEN1 (0.56) CHRM2CYP3A4KMT2AMEN1
SCHEMBL23015299 0.78 LOXL2 (0.59) LMNACHRM2L3MBTL1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 — — EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 — — US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 — — US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 — — US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 — — US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 — — US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 — — US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 — — US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 — — US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 — — EP disclosed
CN-112513020-A KDM1A inhibitors for the treatment of disease 伊美格生物科学公司 2021-03-16 — — CN disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 — — WO disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 — — WO disclosed
US-20170355679-A1 FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES SCIFLUOR LIFE SCIENCES, INC. 2017-12-14 — — US disclosed
US-20170355679-A1 FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES SCIFLUOR LIFE SCIENCES, INC. 2017-12-14 — — US disclosed
US-7795464-B2 Method for producing α-amino acid including phosphorus and production intermediates thereof MEIJI SEIKA KAISHA LTD. (JP) 2010-09-14 — — US disclosed
US-20090270647-A1 METHOD FOR PRODUCING ALPHA - AMINO ACID INCLUDING PHOSPHORUS AND PRODUCTION INTERMEDIATES THEREOF MEIJI SEIKA KAISHA LTD. (JP) 2009-10-29 — — US disclosed
EP-1444982-A1 The use of purine derivatives as selective kinase inhibitors MERCKLE GMBH (DE) 2004-08-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A LMNA 1741/4885CHRM2 4409/4885L3MBTL1 131/4885
US-20090270647-A1 METHOD FOR PRODUCING ALPHA - AMINO ACID INCLUDING PHOSPHORUS AND PRODUCTION INTERMEDIATES THEREOF BCAT1, BCAT2, DAO LMNA 3366/4885CHRM2 1450/4885L3MBTL1 962/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A LMNA 1741/4885CHRM2 4409/4885L3MBTL1 131/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A LMNA 1443/4885CHRM2 4220/4885L3MBTL1 112/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A LMNA 1741/4885CHRM2 4409/4885L3MBTL1 131/4885
US-20170355679-A1 FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES KCNQ2, KCNQ1, KCNQ3 LMNA 2343/4885CHRM2 1179/4885L3MBTL1 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.